Paul Walker

Operates as a holding company which provides investment management services

FTIC’s equity strategies seek to identify stocks it believes to be significantly undervalued in markets across the globe. The strategies are managed in accordance with Sir John Templeton’s investment philosophy and approach, which are based on three tenets: value, patience, and bottom-up stock selection. By combining time-proven fundamental analysis with original research, the investment team searches for companies that meet their criteria of quality and valuation.

MPM BioEquities Adviser focuses exclusively on global life sciences investments. The firm invests in biotechnology, specialty pharmaceuticals, medical technology and related companies that provide innovative medical products and services to the healthcare industry. They invest across all geographies, stages of development and therapeutic areas. MPM focuses on inflection points in the development of companies, such as the achievement of clinical proof-of-concept data and the achievement of early commercial success, and on reinvigorating commercial platforms with potentially high growth assets. MPM BioVentures I (BB BioVentures, MPM BioVentures Parallel Fund) is a family of funds that was launched in 1997 and is no fully committed with 75% of its investments in biotechnology and 25% in medical devices and other healthcare related fields. The MPM BioVentures I portfolio consists of 26 companies with investments ranging from $5 million to $20 million per company. Within the biotechnology sector, the funds' investments are split between companies focused on therapeutics and enabling technologies. About 80% of the funds' assets are invested in US companies and 20% in European companies. The MPM BioVentures II family of funds closed in the first quarter of 2000. The funds consist of investments in biotechnology, medical devices and other healthcare related fields. The MPM BioVentures II has invested in 35 companies, with investments ranging from $10 million to $50 million. The fund has invested across the entire spectrum of company development, from start-up through mezzanine and PIPES. 85% of the funds' investments are in US companies and 15% are in European and Asian companies. The MPM BioVentures III Fund closed in December of 2002. The fund holds a portfolio of 39 companies, 85% of which are focused on biotechnology and pharmaceutical products and 15% are focused on medical devices and life science tools. The fund's balanced portfolio of early-, mid- and late-stage companies includes investments in public companies through PIPE transactions. The MPM BioVentures IV family of funds was launched in the second quarter of 2006. The funds hold a portfolio of 18 companies with investments ranging from $5 million to $36 million. About 75% of the funds' investments focus on biotechnology and pharmaceutical products and 25% focus on medical device companies. About 25% of the funds' investments have been made outside the US, including investments in Asia and Europe. The MPM BioVentures IV family of funds serves as the lead investor in a majority of its investments and takes an active role as a board member on its portfolio companies' boards of directors.

Researches, develops and manufactures medicines & therapies for cancer

Develops and commercializes novel targeted therapeutics for cancer treatment

Operates as a biopharmaceutical company that develops drugs for cancer patients

New Enterprise Associates seeks invests in companies located across the globe. The firm targets companies operating in the fields of technology (software & services, systems, consumer & internet, energy), healthcare (biopharms, devices, services). The firm provides financing for seed, early and growth stage capital requirements.

Functions as a College/University

Operates as a clinical stage biotechnology company that develops innovative therapeutics which target immunomodulatory receptors for the treatment of allergic, inflammatory and proliferative diseases